Advancing Cancer Diagnostics: Volta Labs and Hartwig Medical Unite for Breakthrough Oncological Discoveries
Advancing Cancer Diagnostics: A New Era with Volta Labs and Hartwig Medical
In a groundbreaking partnership, Volta Labs, Inc. and Hartwig Medical Foundation have embarked on a multi-year journey aimed at transforming cancer diagnostics through advanced genomic technologies. Both organizations, recognized leaders in their respective fields, are leveraging the innovative Callisto™ Sample Prep System to improve the processes involved in oncological testing.
The Aim of the Collaboration
This partnership seeks to realize a state-of-the-art sample processing platform designed specifically for prevalent cancer diagnostic sequencing applications. The project entails the development of next-generation sample preparation applications covering a range of techniques, including whole genome sequencing, targeted sequencing, ctDNA analysis, and RNA profiling. The successful launch of the Hybrid Capture app for IDT xGen™ v2 Chemistry denotes a significant milestone in this collaboration, highlighting the efficiencies driven by the Callisto platform.
Breakthroughs in Technology
At the core of this collaboration is the Callisto system, which offers a unique approach to hybrid capture. By providing uniform temperature control and complete automation, it enables an end-to-end, closed-system solution for sequencing. Traditional sequencing preparation has often posed challenges for automation platforms, but the Volta app promises compatibility with the clinically validated OncoAct panel, enhancing cancer mutation profiling.
Edwin Cuppen, Director of Hartwig Medical Foundation, expressed the necessity for a high-quality and consistent system amidst a rapidly evolving oncology landscape. "The demand for sophisticated biomarker testing is increasing, necessitating versatile sample prep technologies that can adapt to the changing needs of laboratories."
Looking Forward
The fruitful integration of Callisto at Hartwig Medical Foundation has led to a commitment to expand their collaborative efforts further. The teams are diligently developing workflows tailored for tissue- and ctDNA-based whole genome sequencing, critical for diagnosing tumors and monitoring disease burden.
Ewart de Bruijn, Innovation Lead at Hartwig, emphasized the promising future of clinical testing enabled by the Callisto platform. This collaboration has the potential to revolutionize routine procedures within accredited clinical workflows, paving the way for enhanced diagnostic accuracy.
Udayan Umapathi, Founder and CEO of Volta Labs, accentuated the significance of this partnership in making complex molecular workflows simple and accessible. The goal is to rethink the oncology pipeline, starting from robust hybrid capture workflows to integrating applications designed for high-sensitivity ctDNA library prep and emerging sequencing platforms.
Conclusion
As Volta Labs and Hartwig Medical Foundation push boundaries in cancer diagnostics, their partnership underscores the importance of innovation and collaboration within the healthcare sector. This initiative not only aims to improve detection and monitoring of various cancers but also fosters a future where genomic testing is integrated seamlessly into clinical practice. Together, they are setting new standards for accuracy and efficiency in the fight against cancer, reaffirming their commitment to enhancing patient care through cutting-edge technology.
This groundbreaking initiative marks a pivotal moment in the field of oncology, showcasing the potential for advancements driven by high-quality genomic research and clinical application. The results of this collaboration will undoubtedly shape the future of cancer diagnostics, providing invaluable insights that aim to enhance patient outcomes across the globe.